TIGIT and neoplasm: Taken together, these data show that ADCC, mediated by DB against tumor cells, leads to a strong induction of the inhibitory receptor TIGIT on effector cells, especially on NK cells, thus further providing a rationale for blocking this inhibiting pathway for an improvement in the antitumor effects of DB-based immunotherapy.